Bliss Bio develops tumor-targeting biopharmaceuticals and antibody-drug conjugates (ADCs) to address unmet clinical needs in cancer treatment. The company focuses on creating differentiated biologic therapies through a combination of in-house research and strategic collaborations, aiming to improve patient outcomes in various tumor indications.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer treatments lack specificity, leading to systemic toxicity and reduced efficacy. There remains a significant unmet need for targeted therapies that selectively eliminate tumor cells while sparing healthy tissue.
Solution
BlissBio is a clinical-stage biotechnology company focused on developing innovative tumor-targeting antibody-drug conjugates (ADCs) and biopharmaceuticals for oncology. The company leverages its proprietary technology platforms and GMP-certified manufacturing facility to create differentiated biologic therapies. BlissBio's pipeline includes multiple ADCs in Phase I and Phase II clinical trials, targeting a variety of oncology indications. Through internal research and strategic collaborations, BlissBio aims to improve patient outcomes by delivering potent cytotoxic payloads directly to cancer cells, minimizing off-target effects.
Target Audience
The primary target audience includes patients with various types of cancer, as well as oncologists and other healthcare professionals involved in cancer treatment.
Features
- Proprietary ADC technology platforms for site-specific drug conjugation and optimized linker design
- GMP-certified manufacturing facility for in-house production of antibodies and ADCs
- Pipeline of tumor-targeting ADCs in Phase I and Phase II clinical trials
- Focus on oncology indications with unmet clinical needs
- Strategic collaborations to accelerate the development and commercialization of innovative biotherapeutics